Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

- PMLiVE

UCB looks to pipeline with five years left for twin blockbusters

CEO outlines pipeline promise, won't write off post-Brexit UK

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

Skills shortage and Brexit will hit R&D, warns UK pharma

Skill shortages and Brexit seen as greatest threat

- PMLiVE

Ministerial revolt looming over ‘no-deal’ Brexit risk

Airbus CEO says no-deal Brexit could force it to relocate

Novartis Gehry Building

Novartis forges AI alliance with Oxford University

Part of Novartis drive to become 'data-driven' pharma company

The UK’s new five-year pricing agreement

Pharma has agreed to capped growth again - in exchange for uptake promises

- PMLiVE

Blackwood returns as new life sciences minister

Replaces James O’Shaughnessy at DHSC

- PMLiVE

Pfizer takeover rumour ignites Amarin shares

Fish oil product shows great promise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links